Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: DISEASE OVERVIEW PART 06: MARKET LANDSCAPE • Market overview • Market size and forecast • Five forces analysis PART 07: PIPELINE LANDSCAPE PART 08: MARKET SEGMENTATION BY DRUG CLASS • Multiclass combination products • NRTIs • Integrase inhibitors • NNRTIs • Others PART 09: REGIONAL LANDSCAPE • Regional comparison • ART market in Americas • ART market in EMEA • ART market in APAC • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Significant pipeline • Advanced formulations • Funding and treatment initiatives PART 13: VENDOR LANDSCAPE • Vendor landscape PART 14: KEY VENDOR ANALYSIS • Gilead • ViiV Healthcare • Janssen Pharmaceuticals • F. Hoffmann-La Roche • Other prominent vendors PART 15: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Global ART market Exhibit 02: Global ART market 2016-2021 ($ millions) Exhibit 03: Five forces analysis Exhibit 04: Pipeline landscape by development phase Exhibit 05: Key clinical trials Exhibit 06: Global ART market by drug class 2016 Exhibit 07: Global ART market by drug class 2021 Exhibit 08: Global ART market by multiclass combination products 2016-2021 ($ millions) Exhibit 09: Global ART market by NRTIs 2016-2021 ($ millions) Exhibit 10: Global ART market by integrase inhibitors 2016-2021 ($ millions) Exhibit 11: Global ART market by NNRTIs 2016-2021 ($ millions) Exhibit 12: Global ART market by others 2016-2021 ($ millions) Exhibit 13: Global ART market: Regional landscape Exhibit 14: Regional comparison Exhibit 15: ART market in Americas 2016-2021 ($ millions) Exhibit 16: ART market in Americas – Year over year growth 2017-2021 Exhibit 17: ART market in EMEA 2016-2021 ($ millions) Exhibit 18: ART market in EMEA – Year over year growth 2017-2021 Exhibit 19: ART market in APAC 2016-2021 ($ millions) Exhibit 20: ART market in APAC – Year over year growth 2017-2021 Exhibit 21: Gilead: Key highlights Exhibit 22: Gilead: Strength assessment Exhibit 23: Gilead: Strategy assessment Exhibit 24: Gilead: Opportunity assessment Exhibit 25: ViiV Healthcare: Key highlights Exhibit 26: ViiV Healthcare: Strength assessment Exhibit 27: ViiV Healthcare: Strategy assessment Exhibit 28: ViiV Healthcare: Opportunity assessment Exhibit 29: Janssen Pharmaceuticals: Key highlights Exhibit 30: Janssen Pharmaceuticals: Strength assessment Exhibit 31: Janssen Pharmaceuticals: Strategy assessment Exhibit 32: Janssen Pharmaceuticals: Opportunity assessment Exhibit 33: F. Hoffmann-La Roche: Key highlights Exhibit 34: F. Hoffmann-La Roche: Strength assessment Exhibit 35: F. Hoffmann-La Roche: Strategy assessment Exhibit 36: F. Hoffmann-La Roche: Opportunity assessment

Gilead, ViiV Healthcare, Janssen Pharmaceuticals, F. Hoffmann-La Roche, Abbvie, Boehringer Ingelheim, Bionor Pharma, Vertex Pharmaceuticals, and Mylan